Daxor Corporation Common Stock(DXR)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841)
- Exchange
- XNAS
- Market Cap
- $0.1B
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -4.86% | 6 |
| Feb | -5.31% | 6 |
| Mar | +4.62% | 6 |
| Apr | +3.16% | 6 |
| May | -3.69% | 6 |
| Jun | +5.06% | 6 |
| Jul | -1.07% | 5 |
| Aug | -0.05% | 5 |
| Sep | +9.88% | 5 |
| Oct | -7.84% | 5 |
| Nov | -0.09% | 5 |
| Dec | +2.72% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.40
- Correlation (SPY)
- 9.3%
- R²
- 0.01
- Ann. Volatility
- 53.5%
- SPY Volatility
- 12.4%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-10 | Michael Richard Feldschuh | Chief Executive Officer | Buy (P) | +1,000 | $9.07 | $9.1K | EDGAR |
| 2026-03-24 | John Jefferies | Chief Medical Officer | Buy (P) | +5,941 | — | EDGAR | |
| 2025-12-11 | Jonathan Adam Feldschuh | Chief Scientific Officer | Buy (P) | +18,000 | — | EDGAR | |
| 2025-12-11 | Robert J Michel | Chief Financial Officer | Buy (P) | +3,000 | — | EDGAR | |
| 2025-11-14 | John Jefferies | Chief Medical Officer | Buy (P) | +2,344 | — | EDGAR | |
| 2025-06-26 | Caleb DesRosiers | Director | Grant (A) | +2,500 opt | — | EDGAR | |
| 2025-06-26 | Joy S. Goudie | Director | Grant (A) | +2,500 opt | — | EDGAR | |
| 2025-06-26 | Edward Feuer | Director | Grant (A) | +2,500 opt | — | EDGAR | |
| 2025-06-26 | Henry D. Cremisi | Director | Grant (A) | +2,500 opt | — | EDGAR | |
| 2025-04-07 | Michael Richard Feldschuh | Chief Executive Officer | Buy (P) | +2,063 | $7.89 | $16.3K | EDGAR |
| 2025-03-27 | Michael Richard Feldschuh | Chief Executive Office | Buy (P) | +1,000 | $8.13 | $8.1K | EDGAR |
| 2025-03-20 | Michael Richard Feldschuh | Chief Executive Officer | Buy (P) | +1,492 | $7.72 | $11.5K | EDGAR |
| 2025-03-20 | Michael Richard Feldschuh | Chief Executive Officer | Buy (P) | +647 | $8.15 | $5.3K | EDGAR |
| 2025-03-11 | Robert J Michel | Chief Financial Officer | Buy (P) | +1,000 | $8.00 | $8.0K | EDGAR |
| 2025-03-11 | Michael Richard Feldschuh | Chief Executive Officer | Buy (P) | +3,360 | $7.68 | $25.8K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | JOSEPH FELDSCHUH | Chairman | 3,174,455 | $29.40M | $1.44M | 91 | 2018-03-19 |
| 2 | of Joseph Feldschuh Estate | 10%+ Owner | 2,549,455 | $23.61M | $0 | 2 | 2023-09-20 |
| 3 | Michael Richard Feldschuh | Chief Executive Officer | 213,694 | $1.98M | -$120.7K | 36 | 2026-04-10 |
| 4 | Philip Nordan Hudson | Director | 146,100 | $1.35M | $55.7K | 9 | 2012-03-28 |
| 5 | Jonathan Adam Feldschuh | Chief Scientific Officer | 53,908 | $499.2K | -$357.6K | 5 | 2025-12-11 |
| 6 | John Jefferies | Chief Medical Officer | 21,272 | $197.0K | $0 | 2 | 2026-03-24 |
| 7 | Robert J Michel | Chief Financial Officer | 20,050 | $185.7K | $73.9K | 16 | 2025-12-11 |
| 8 | ROBERT WILLENS | Director | 18,164 | $168.2K | $104.4K | 12 | 2013-05-10 |
| 9 | MARTIN S WOLPOFF | Director | 4,000 | $37.0K | $11.8K | 9 | 2020-07-15 |
| 10 | Caleb DesRosiers | Director | 3,157 | $29.2K | $30.0K | 5 | 2025-06-26 |
| 11 | Soren Thompson | VP, Business Development | 1,950 | $18.1K | -$59.9K | 3 | 2018-08-02 |
| 12 | Edward Feuer | Director | 1,000 | $9.3K | $16.5K | 9 | 2025-06-26 |
| 13 | Diane Marie Meegan | Corporate Secretary | 500 | $4.6K | $1.2K | 2 | 2015-04-13 |
| 14 | Everis Engstrom | Vice President | 500 | $4.6K | $8.0K | 1 | 2008-12-05 |
| 15 | Joy S. Goudie | Director | 300 | $2.8K | $2.9K | 7 | 2025-06-26 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.